LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary
care services, is set to join the broad-market Russell 3000® Index
at the conclusion of the 2024 Russell U.S. Indexes annual
reconstitution, effective at the open of U.S. equity markets on
Monday, July 1st, according to a preliminary list of additions
posted Friday, May 24th.
The annual Russell U.S. Indexes reconstitution
captures the 4,000 largest U.S. stocks as of Tuesday, April 30th,
ranking them by total market capitalization. Membership in the U.S.
all-cap Russell 3000® Index, which remains in place for one year,
means automatic inclusion in the large-cap Russell 1000® Index or
the small-cap Russell 2000® Index, as well as the appropriate
growth and value style indexes. FTSE Russell determines membership
for its Russell indexes primarily by objective,
market-capitalization rankings, and style attributes.
“Achieving a place in the Russell 2000® Index is
testament to the hard work of my LifeMD colleagues and the success
we’ve had in bringing affordable primary care, weight loss and
other healthcare services to a growing number of patients
nationwide,” said Justin Schreiber, Chairman and CEO of LifeMD.
Russell indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. According to the data
as of the end of December 2023, about $10.5 trillion in assets are
benchmarked against the Russell U.S. indexes, which belong to FTSE
Russell, a prominent global index provider.
“Russell indexes – now in their 40th year –
continue to evolve to reflect the dynamic U.S. economy. Annual
rebalancing plays a vital role in establishing accurate benchmarks,
ensuring they correctly mirror their designated market segments and
remain unbiased in terms of size and style,” said Fiona Bassett,
CEO of FTSE Russell, an LSEG Business.
For more information on the Russell 3000® Index
and the Russell indexes reconstitution, go to the “Russell
Reconstitution” section on the FTSE Russell website.
About FTSE Russell
FTSE Russell is a leading global provider of
benchmarking, analytics and data solutions for investors, giving
them a precise view of the market relevant to their investment
process. A comprehensive range of reliable and accurate indexes
provides investors worldwide with the tools they require to measure
and benchmark markets across asset classes, styles or
strategies.
FTSE Russell index expertise and products are
used extensively by institutional and retail investors globally.
For over 30 years, leading asset owners, asset managers, ETF
providers and investment banks have chosen FTSE Russell indexes to
benchmark their investment performance and create ETFs, structured
products and index-based derivatives.
FTSE Russell is focused on applying the highest
industry standards in index design and governance, employing
transparent rules-based methodology informed by independent
committees of leading market participants. FTSE Russell fully
embraces the IOSCO Principles, and its Statement of Compliance has
received independent assurance. Index innovation is driven by
client needs and customer partnerships, allowing FTSE Russell to
continually enhance the breadth, depth and reach of its
offering.
FTSE Russell is wholly owned by London Stock
Exchange Group. For more information, visit
https://www.lseg.com/en/ftse-russell.
About LifeMD
LifeMD is a leading provider of virtual primary
care. LifeMD offers telemedicine, laboratory and pharmacy services,
and specialized treatment across more than 200 conditions including
primary care, men’s and women's health, weight management and
hormone therapy. The Company leverages a
vertically-integrated, proprietary digital care platform, a
50-state affiliated medical group and a U.S.-based patient care
center to increase access to high-quality and affordable care.
For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking
Statements
This news release includes forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended; Section 21E of the Securities Exchange Act of
1934, as amended; and the safe harbor provision of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements contained in this news release may be identified by the
use of words such as: “believe,” “expect,” “anticipate,” “project,”
“should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,”
“continue,” and “potential,” or, in each case, their negative or
other variations or comparable terminology referencing future
periods. Examples of forward-looking statements include, but are
not limited to, statements regarding our financial outlook and
guidance, short and long-term business performance and operations,
future revenues and earnings, regulatory developments, legal events
or outcomes, ability to comply with complex and evolving
regulations, market conditions and trends, new or expanded products
and offerings, growth strategies, underlying assumptions, and the
effects of any of the foregoing on our future results of operations
or financial condition.
Forward-looking statements are not historical
facts and are not assurances of future performance. Rather, these
statements are based on our current expectations, beliefs, and
assumptions regarding future plans and strategies, projections,
anticipated and unanticipated events and trends, the economy, and
other future conditions, including the impact of any of the
aforementioned on our future business. As forward-looking
statements relate to the future, they are subject to inherent risk,
uncertainties, and changes in circumstances and assumptions that
are difficult to predict, including some of which are out of our
control. Consequently, our actual results, performance, and
financial condition may differ materially from those indicated in
the forward-looking statements. These risks and uncertainties
include, but are not limited to, “Risk Factors” identified in our
filings with the Securities and Exchange Commission, including, but
not limited to, our most recently filed Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, and any amendments thereto. Even if
our actual results, performance, or financial condition are
consistent with forward-looking statements contained in such
filings, they may not be indicative of our actual results,
performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news
release is based on information currently available to us as of the
date on which this release is made. We undertake no obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or otherwise, except as may be
required under applicable law or regulation.
Investor ContactMarc Benathen,
CFOmarc@lifemd.com
Media ContactJessica Friedeman,
Chief Marketing Officerpress@lifemd.com
LifeMD (NASDAQ:LFMDP)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
LifeMD (NASDAQ:LFMDP)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024